SEC Comment Letter 0000000000-23-014118 to Theratechnologies Inc. (THTX) (CIK 0001512717)
Theratechnologies Inc. (THTX) (CIK 0001512717)
Date: Dec. 27, 2023 · CIK: 0001512717 · Accession: 0000000000-23-014118
AI Filing Summary & Sentiment
File numbers found in text: 333-276196
Letter
United States securities and exchange commission logo December 27, 2023 Paul Lévesque President and Chief Executive Officer Theratechnologies, Inc. 2015 Peel Street, Suite 1100 Montréal, QC H3A 1T8 Re:Theratechnologies, Inc. Registration Statement on Form F-3 Filed December 21, 2023 File No. 333-276196 Dear Paul Lévesque: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Martin Glass, Esq.
Show Raw Text
United States securities and exchange commission logo
December 27, 2023
Paul Lévesque
President and Chief Executive Officer
Theratechnologies, Inc.
2015 Peel Street, Suite 1100
Montréal, QC H3A 1T8
Re:Theratechnologies, Inc.
Registration Statement on Form F-3
Filed December 21, 2023
File No. 333-276196
Dear Paul Lévesque:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Martin Glass, Esq.